Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00651118 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 832
- Enrollment target
NCT00651118: Completed Phase 3 study, sponsored by Meda Pharmaceuticals.
NCT00651118 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 832 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00651118, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 832 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if two allergy medications (azelastine and fluticasone) are more effective than placebo or either medication alone (azelastine or fluticasone)
Primary Outcome
change from baseline in 12-hour reflective(how did you feel in the last 12 hours) total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period. The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.The more negative value the better the result.
Interventions
- DRUG Placebo
- DRUG azelastine Hcl
- DRUG fluticasone propionate
- DRUG azelastineHcl / fluticasone propionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 832 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
What the finished NCT00651118 record still lists
NCT00651118 is an interventional study that assigns participants to a tested intervention. The registered 832 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00651118 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00651118 about?
NCT00651118 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies". The purpose of this study is to determine if two allergy medications (azelastine and fluticasone) are more effective than placebo or either medication alone (azelastine or fluticasone)
What is the current status of trial NCT00651118?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 832 participants. The study started on 2008-03. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00651118?
The interventions under investigation include: Placebo (DRUG), azelastine Hcl (DRUG), fluticasone propionate (DRUG), azelastineHcl / fluticasone propionate (DRUG).
Who is sponsoring clinical trial NCT00651118?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00651118's enrollment target sits among peer trials
832 397th of 2000 higher than 1,604 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06910553 · 832 participants
IBD Pregnancy Registry
- NCT07089706 · 832 participants · Phase 4
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia